Concurrence of nivolumab‐induced interstitial lung disease and cancer invasion

Nivolumab improves overall survival rates of patients with advanced or recurrent non‐small‐cell lung cancer (NSCLC). Among immune‐related adverse events caused by nivolumab, interstitial lung disease (ILD) is a clinically serious and potentially life‐threatening toxicity, for which appropriate treat...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Respirol Case Rep
Main Authors: Kanai, Osamu, Nakatani, Koichi, Fujita, Kohei, Okamura, Misato, Mio, Tadashi
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley & Sons, Ltd 2017
Fag:
Case Reports
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5553297/
https://ncbi.nlm.nih.gov/pubmed/28811904
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.257
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker